

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: LaPorte Hospital Company, LLC d/b/a LaPorte Hospital 1007 Lincolnway LaPorte, IN 46350 REPORT NUMBER(S) 2018001	2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352
--	---

3. DOCKET NUMBER(S) 030-08653	4. LICENSE NUMBER(S) 13-15151-01	5. DATE(S) OF INSPECTION May 25, 2018
--------------------------------------	---	--

6. INSPECTION PROCEDURES USED 87131, 87132	7. INSPECTION FOCUS AREAS All
---	--------------------------------------

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 02240	2. PRIORITY 2	3. LICENSEE CONTACT James Hatten - RSO	4. TELEPHONE NUMBER (815) 370-6538
---------------------------------	----------------------	---	---

Main Office Inspection Next Inspection Date: 05/25/2020

Field Office Inspection _____

Temporary Job Site Inspection _____

PROGRAM SCOPE

This was an unannounced routine inspection of a community hospital authorized to use byproduct material for diagnostic and therapeutic medical purposes at its facility in LaPorte, Indiana. At the time of the inspection, three technologists (two full-time and one part-time) performed around four diagnostic administrations per day, Monday through Friday, using unit doses only. The licensee performed 3-4 therapeutic administrations of I-131 in each of the last three years, but none using Ra-223 Xofigo since before the previous inspection. The licensee had been performing 25-30 administrations of Y-90 microspheres annually, but so far has only performed one in 2018. The licensee retained the services of a consulting physicist (who served as RSO and who audited program quarterly) and maintained a Radiation Safety Committee (RSC), which met at least annually.

PERFORMANCE OBSERVATIONS

The inspector toured the hospital in LaPorte to evaluate the licensee's measures for materials security, hazard communication, and exposure control. The inspector conducted independent surveys of the facility, and found no evidence of residual contamination in unrestricted areas, nor any exposure rates in excess of regulatory limits to members of the public. The inspector observed the administration of two unit doses for a cardiac stress test and one for a gastric emptying study, as well as the receipt of packages containing radioactive material. The staff also demonstrated the implementation of licensee procedures for area surveys, spill response and decay in storage waste handling.

The inspector reviewed all written directives for I-131 and Y-90 microsphere administrations performed since the last inspection, and found that the licensee's procedures provided high confidence that the treatments were performed in accordance with these written directives via capsule assays (for I-131) and via post-injection surveys and SPECT imaging (for microspheres). The inspector also reviewed a selection of other records, including RSC meeting minutes, consultant audits, personnel dosimetry reports, procedures for the safe use of radioactive materials, survey meter calibration records, and various other routine nuclear medicine documentation.

No violations of NRC requirements were identified as a result of this inspection.